Table 1 Top 20 pathways altered in FCdR treated cells
# | Pathway | DEGs with pathway annotation (594) | All genes with pathway annotation (9952) | Pvalue | Qvalue | Pathway ID |
|---|---|---|---|---|---|---|
1 | p53 signaling pathway | 16 (2.69%) | 67 (0.67%) | 1.38E-06 | 1.56E-04 | ko04115 |
2 | Colorectal cancer | 14 (2.36%) | 62 (0.62%) | 1.26E-05 | 9.54E-04 | ko05210 |
3 | Nucleotide excision repair | 12 (2.02%) | 48 (0.48%) | 1.75E-05 | 9.94E-04 | ko03420 |
4 | DNA replication | 10 (1.68%) | 36 (0.36%) | 3.28E-05 | 1.49E-03 | ko03030 |
5 | Cell cycle | 20 (3.37%) | 128 (1.29%) | 6.57E-05 | 2.49E-03 | ko04110 |
6 | Pathways in cancer | 36 (6.06%) | 323 (3.25%) | 2.06E-04 | 6.00E-03 | ko05200 |
7 | Limonene and pinene degradation | 3 (0.51%) | 3 (0.03%) | 2.12E-04 | 6.00E-03 | ko00903 |
8 | Biosynthesis of secondary metabolites | 26 (4.38%) | 225 (2.26%) | 8.97E-04 | 2.26E-02 | ko01110 |
9 | Metabolic pathways | 92 (15.49%) | 1132 (11.37%) | 1.07E-03 | 2.43E-02 | ko01100 |
10 | Benzoate degradation | 4 (0.67%) | 9 (0.09%) | 1.24E-03 | 2.57E-02 | ko00362 |
11 | Mismatch repair | 6 (1.01%) | 23 (0.23%) | 1.86E-03 | 3.26E-02 | ko03430 |
12 | Prostate cancer | 13 (2.19%) | 88 (0.88%) | 2.05E-03 | 3.26E-02 | ko05215 |
13 | Cell cycle - yeast | 11 (1.85%) | 68 (0.68%) | 2.13E-03 | 3.26E-02 | ko04111 |
14 | Bladder cancer | 8 (1.35%) | 40 (0.4%) | 2.16E-03 | 3.26E-02 | ko05219 |
15 | Meiosis - yeast | 10 (1.68%) | 59 (0.59%) | 2.35E-03 | 3.33E-02 | ko04113 |
16 | Ribosome | 13 (2.19%) | 90 (0.9%) | 2.52E-03 | 3.36E-02 | ko03010 |
17 | Adherens junction | 11 (1.85%) | 70 (0.7%) | 2.70E-03 | 3.41E-02 | ko04520 |
18 | Base excision repair | 7 (1.18%) | 34 (0.34%) | 3.41E-03 | 4.04E-02 | ko03410 |
19 | Naphthalene degradation | 2 (0.34%) | 2 (0.02%) | 3.56E-03 | 4.04E-02 | ko00626 |
20 | Focal adhesion | 22 (3.7%) | 199 (2%) | 3.76E-03 | 4.06E-02 | ko04510 |